NeoGenomics, Inc. (NEO)
USD 16.49
(-6.04%)
USD 16.49
(-6.04%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -17.6 Million USD | 92.23% |
| 2022 | -78.63 Million USD | -293.48% |
| 2021 | 52.07 Million USD | 29.08% |
| 2020 | 34.85 Million USD | -13.09% |
| 2019 | 43.26 Million USD | 21.58% |
| 2018 | 31.78 Million USD | 28.95% |
| 2017 | 26.55 Million USD | -15.72% |
| 2016 | 29.24 Million USD | 733.96% |
| 2015 | 3.5 Million USD | 58.12% |
| 2014 | 7.85 Million USD | -30.12% |
| 2013 | 7.58 Million USD | -36.89% |
| 2012 | 5.02 Million USD | 200.06% |
| 2011 | 1.67 Million USD | 207.99% |
| 2010 | -812 Thousand USD | -176.9% |
| 2009 | -526.31 Thousand USD | -265.5% |
| 2008 | -143.42 Thousand USD | 94.23% |
| 2007 | -2.63 Million USD | -780.69% |
| 2006 | 446.58 Thousand USD | 163.07% |
| 2005 | -619.29 Thousand USD | 0.96% |
| 2004 | -625.3 Thousand USD | -40.11% |
| 2003 | -446.29 Thousand USD | 23.54% |
| 2002 | -583.67 Thousand USD | 92.55% |
| 2001 | -7.83 Million USD | -728.66% |
| 2000 | -944.52 Thousand USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -2.29 Million USD | 109.78% |
| 2024 Q3 | -21.19 Million USD | 135.19% |
| 2024 Q1 | -9.9 Million USD | -262.51% |
| 2023 Q3 | -1.81 Million USD | 66.98% |
| 2023 Q4 | 8.65 Million USD | 577.65% |
| 2023 FY | - USD | 92.23% |
| 2023 Q1 | -7.87 Million USD | 66.22% |
| 2023 Q2 | -5.48 Million USD | 30.3% |
| 2022 Q3 | -22.02 Million USD | 2.94% |
| 2022 Q1 | -35.14 Million USD | 17.3% |
| 2022 Q4 | -23.31 Million USD | -5.86% |
| 2022 FY | - USD | -293.48% |
| 2022 Q2 | -22.68 Million USD | 35.44% |
| 2021 Q1 | -10.82 Million USD | -155.82% |
| 2021 Q2 | 85.03 Million USD | 885.72% |
| 2021 Q4 | -42.49 Million USD | -713.81% |
| 2021 FY | - USD | 29.08% |
| 2021 Q3 | -5.22 Million USD | -106.14% |
| 2020 Q4 | 19.39 Million USD | 41.78% |
| 2020 Q2 | -3.09 Million USD | -185.53% |
| 2020 Q1 | 3.62 Million USD | -65.19% |
| 2020 FY | - USD | -13.09% |
| 2020 Q3 | 13.67 Million USD | 541.45% |
| 2019 Q4 | 10.4 Million USD | -4.74% |
| 2019 Q3 | 10.92 Million USD | -9.82% |
| 2019 Q2 | 12.11 Million USD | 132.52% |
| 2019 Q1 | 5.2 Million USD | -41.25% |
| 2019 FY | - USD | 21.58% |
| 2018 Q1 | 7.61 Million USD | -22.89% |
| 2018 Q2 | 5.9 Million USD | -22.48% |
| 2018 Q3 | 9.4 Million USD | 59.34% |
| 2018 Q4 | 8.86 Million USD | -5.71% |
| 2018 FY | - USD | 28.95% |
| 2017 Q3 | 2.22 Million USD | -68.1% |
| 2017 FY | - USD | -15.72% |
| 2017 Q4 | 9.87 Million USD | 344.37% |
| 2017 Q2 | 6.96 Million USD | 24.64% |
| 2017 Q1 | 5.58 Million USD | -17.0% |
| 2016 Q3 | 7.43 Million USD | -1.5% |
| 2016 FY | - USD | 733.96% |
| 2016 Q1 | 7.53 Million USD | 334.31% |
| 2016 Q2 | 7.54 Million USD | 0.19% |
| 2016 Q4 | 6.73 Million USD | -9.42% |
| 2015 Q1 | -561 Thousand USD | -142.53% |
| 2015 Q4 | -3.21 Million USD | -2920.18% |
| 2015 Q3 | 114 Thousand USD | 307.14% |
| 2015 FY | - USD | 58.12% |
| 2015 Q2 | 28 Thousand USD | 104.99% |
| 2014 Q4 | 1.31 Million USD | 1906.85% |
| 2014 FY | - USD | -30.12% |
| 2014 Q1 | 394 Thousand USD | -67.28% |
| 2014 Q2 | 578 Thousand USD | 46.7% |
| 2014 Q3 | -73 Thousand USD | -112.63% |
| 2013 Q3 | 1.16 Million USD | 129.7% |
| 2013 Q2 | 505 Thousand USD | 65.57% |
| 2013 Q1 | 305 Thousand USD | -77.22% |
| 2013 FY | - USD | -36.89% |
| 2013 Q4 | 1.2 Million USD | 3.79% |
| 2012 Q1 | 1.62 Million USD | 66.39% |
| 2012 FY | - USD | 200.06% |
| 2012 Q4 | 1.33 Million USD | 323.73% |
| 2012 Q2 | 1.75 Million USD | 7.82% |
| 2012 Q3 | 316 Thousand USD | -81.95% |
| 2011 Q2 | 361 Thousand USD | 261.88% |
| 2011 FY | - USD | 207.99% |
| 2011 Q3 | 563 Thousand USD | 55.96% |
| 2011 Q4 | 976 Thousand USD | 73.36% |
| 2011 Q1 | -223 Thousand USD | -182.28% |
| 2010 Q4 | -79 Thousand USD | 85.71% |
| 2010 FY | - USD | -176.9% |
| 2010 Q3 | -553 Thousand USD | -47.86% |
| 2010 Q1 | -432 Thousand USD | 57.54% |
| 2010 Q2 | -374 Thousand USD | 13.43% |
| 2009 FY | - USD | -265.5% |
| 2009 Q3 | -315.57 Thousand USD | -178.02% |
| 2009 Q4 | -1.01 Million USD | -222.38% |
| 2009 Q1 | 385.05 Thousand USD | 174.66% |
| 2009 Q2 | 404.45 Thousand USD | 5.04% |
| 2008 Q2 | 308.82 Thousand USD | 673.48% |
| 2008 FY | - USD | 94.23% |
| 2008 Q4 | -515.72 Thousand USD | -539.57% |
| 2008 Q3 | 117.32 Thousand USD | -62.01% |
| 2008 Q1 | -53.85 Thousand USD | 96.22% |
| 2007 Q1 | -132.2 Thousand USD | 55.7% |
| 2007 Q3 | -545.8 Thousand USD | 13.54% |
| 2007 Q4 | -1.42 Million USD | -160.95% |
| 2007 FY | - USD | -780.69% |
| 2007 Q2 | -631.25 Thousand USD | -377.48% |
| 2006 Q4 | -298.44 Thousand USD | -248.13% |
| 2006 FY | - USD | 163.07% |
| 2006 Q3 | 201.47 Thousand USD | -35.57% |
| 2006 Q2 | 312.7 Thousand USD | 35.46% |
| 2006 Q1 | 230.85 Thousand USD | 184.18% |
| 2005 FY | - USD | 0.96% |
| 2005 Q1 | -161 Thousand USD | 35.03% |
| 2005 Q4 | -274.23 Thousand USD | -202.37% |
| 2005 Q3 | -90.69 Thousand USD | 2.85% |
| 2005 Q2 | -93.36 Thousand USD | 42.01% |
| 2004 Q3 | -122.99 Thousand USD | -1.83% |
| 2004 Q2 | -120.78 Thousand USD | 9.66% |
| 2004 FY | - USD | -40.11% |
| 2004 Q1 | -133.69 Thousand USD | -14.1% |
| 2004 Q4 | -247.82 Thousand USD | -101.48% |
| 2003 Q1 | -98.67 Thousand USD | -106.74% |
| 2003 Q4 | -117.18 Thousand USD | -4.05% |
| 2003 FY | - USD | 23.54% |
| 2003 Q3 | -112.61 Thousand USD | 4.42% |
| 2003 Q2 | -117.82 Thousand USD | -19.41% |
| 2002 Q4 | 1.46 Million USD | 755.24% |
| 2002 Q1 | -83.76 Thousand USD | 98.84% |
| 2002 Q3 | -223.58 Thousand USD | -127.61% |
| 2002 FY | - USD | 92.55% |
| 2002 Q2 | 287.84 Thousand USD | 1066.66% |
| 2001 Q2 | -214.59 Thousand USD | 37.77% |
| 2001 Q4 | -7.22 Million USD | -2398.48% |
| 2001 Q1 | -344.81 Thousand USD | 47.3% |
| 2001 Q3 | -289.34 Thousand USD | -34.83% |
| 2001 FY | - USD | -728.66% |
| 2000 Q2 | -204.52 Thousand USD | -33.71% |
| 2000 Q3 | 66.66 Thousand USD | 132.6% |
| 2000 Q4 | -654.34 Thousand USD | -1081.51% |
| 2000 FY | - USD | 0.0% |
| 2000 Q1 | -152.32 Thousand USD | 0.0% |
| 1999 Q1 | -99.04 Thousand USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Bionano Genomics, Inc. | -213.6 Million USD | 91.757% |
| Prenetics Global Limited | -47.89 Million USD | 63.239% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -943.687% |
| CareDx, Inc | -89.65 Million USD | 80.362% |
| Exact Sciences Corporation | 41.87 Million USD | 142.046% |
| Exagen Inc. | -19.15 Million USD | 8.072% |
| Inotiv, Inc. | -26.5 Million USD | 33.574% |
| Guardant Health, Inc. | -433.3 Million USD | 95.937% |
| Biodesix, Inc. | -37.1 Million USD | 52.546% |
| BioNexus Gene Lab Corp. | -2.48 Million USD | -608.485% |
| Precipio, Inc. | -4.31 Million USD | -307.758% |
| iSpecimen Inc. | -9.1 Million USD | -93.404% |
| Natera, Inc. | -383.27 Million USD | 95.406% |
| Aspira Women's Health Inc. | -16.49 Million USD | -6.767% |
| Standard BioTools Inc. | -54.45 Million USD | 67.668% |
| 23andMe Holding Co. | -291.87 Million USD | 93.968% |
| Castle Biosciences, Inc. | -45.02 Million USD | 60.894% |
| Personalis, Inc. | -96.8 Million USD | 81.812% |
| Aclaris Therapeutics, Inc. | -117.56 Million USD | 85.024% |
| Applied DNA Sciences, Inc. | -9.59 Million USD | -83.578% |
| OpGen, Inc. | -29.51 Million USD | 40.338% |
| T2 Biosystems, Inc. | -43.87 Million USD | 59.87% |
| Myriad Genetics, Inc. | -67.8 Million USD | 74.031% |
| ICON Public Limited Company | 1.63 Billion USD | 101.079% |
| Star Equity Holdings, Inc. | -1.68 Million USD | -943.687% |
| IDEXX Laboratories, Inc. | 1.21 Billion USD | 101.446% |
| RadNet, Inc. | 292.78 Million USD | 106.014% |
| MDxHealth SA | -30.46 Million USD | 42.212% |
| Psychemedics Corporation | -251 Thousand USD | -6914.741% |
| Illumina, Inc. | -608 Million USD | 97.104% |
| Check-Cap Ltd. | -17.64 Million USD | 0.238% |
| Twist Bioscience Corporation | -176.7 Million USD | 90.036% |
| DarioHealth Corp. | -53.49 Million USD | 67.086% |
| Fulgent Genetics, Inc. | -46.55 Million USD | 62.178% |
| Sera Prognostics, Inc. | -35.28 Million USD | 50.103% |
| ENDRA Life Sciences Inc. | -9.78 Million USD | -79.942% |
| OPKO Health, Inc. | -65.51 Million USD | 73.126% |
| Medpace Holdings, Inc. | 363.15 Million USD | 104.848% |
| Neogen Corporation | 182.59 Million USD | 109.643% |
| Intelligent Bio Solutions Inc. | -8.81 Million USD | -99.836% |
| Prenetics Global Limited | -47.89 Million USD | 63.239% |
| Mainz Biomed B.V. | -25.01 Million USD | 29.604% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -130.781% |
| Trinity Biotech plc | -24.09 Million USD | 26.936% |
| Neuronetics, Inc. | -22.75 Million USD | 22.637% |
| Sotera Health Company | 514.14 Million USD | 103.425% |
| bioAffinity Technologies, Inc. | -7.62 Million USD | -130.781% |